What is the deciding factor in a clinician’s choice of drug?
The importance of biomarkers in treating melanoma patients
Educating patients about their cancer
Proton beam therapy in the UK: usage and monitoring
The promise of PARP inhibitors and their emerging role in ovarian cancer